National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
Department for Viral Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan 250014, China.
Viruses. 2022 Apr 15;14(4):822. doi: 10.3390/v14040822.
Nineteen CVA9 isolates were obtained between 2010 and 2019 from six provinces of mainland China, using the HFMD surveillance network established in China. Nucleotide sequencing revealed that the full-length VP1 of 19 CVA9 isolates was 906 bases encoding 302 amino acids. The combination of the thresholds of the phylogenetic tree and nucleotide divergence of different genotypes within the same serotype led to a value of 15-25%, and enabled CVA9 worldwide to be categorized into ten genotypes: A-J. The phylogenetic tree showed that the prototype strain was included in genotype A, and that the B, C, D, E, H, and J genotypes disappeared during virus evolution, whereas the F, I, and G genotypes showed co-circulation. Lineage G was the dominant genotype of CVA9 and included most of the strains from nine countries in Asia, North America, Oceania, and Europe. Most Chinese strains belonged to the G genotype, suggesting that the molecular epidemiology of China is consistent with that observed worldwide. The 165 partial VP1 strains (723 nt) showed a mean substitution rate of 3.27 × 10 substitution/site/year (95% HPD range 2.93-3.6 × 10), dating the tMRCA of CVA9 back to approximately 1922 (1911-1932). The spatiotemporal dynamics of CVA9 showed the spread of CVA9 obviously increased in recent years. Most CVA9 isolates originated in USA, but the epidemic areas of CVA9 are now concentrated in the Asia-Pacific region, European countries, and North America. Recombination analysis within the enterovirus B specie (59 serotypes) revealed eight recombination patterns in China at present, CVB4, CVB5, E30, CVB2, E11, HEV106, HEV85, and HEV75. E14, and E6 may act as recombinant donors in multiple regions. Comparison of temperature sensitivity revealed that temperature-insensitive strains have more amino acid substitutions in the RGD motif of the VP1 region, and the sites T283S, V284M, and R288K in the VP1 region may be related to the temperature tolerance of CVA9.
19 株 CVA9 分离株于 2010 年至 2019 年期间从中国六个省份通过中国建立的手足口病监测网络获得。核苷酸序列分析显示,19 株 CVA9 分离株全长 VP1 为 906 个碱基,编码 302 个氨基酸。基于种系发生树的阈值和同一血清型内不同基因型的核苷酸差异的组合,确定了 15%-25%的界限值,使全球范围内的 CVA9 分为 10 个基因型:A-J。系统进化树显示,原型株属于基因型 A,B、C、D、E、H 和 J 基因型在病毒进化过程中消失,而 F、I 和 G 基因型则同时存在。谱系 G 是 CVA9 的优势基因型,包含来自亚洲、北美、大洋洲和欧洲的九个国家的大多数菌株。大多数中国菌株属于 G 基因型,表明中国的分子流行病学与全球观察结果一致。165 株部分 VP1 株(723 nt)的平均替换率为 3.27×10-3 替换/位点/年(95% HPD 范围为 2.93-3.6×10-3),表明 CVA9 的 tMRCA 可追溯到大约 1922 年(1911-1932 年)。CVA9 的时空动态显示,近年来 CVA9 的传播明显增加。大多数 CVA9 分离株源自美国,但目前 CVA9 的流行地区集中在亚太地区、欧洲国家和北美地区。目前在中国肠病毒 B 种(59 个血清型)内的重组分析显示,有 8 种重组模式,即 CVB4、CVB5、E30、CVB2、E11、HEV106、HEV85 和 HEV75。E14 和 E6 可能在多个地区充当重组供体。对温度敏感性的比较表明,温度不敏感株在 VP1 区的 RGD 基序中具有更多的氨基酸取代,VP1 区的 T283S、V284M 和 R288K 位点可能与 CVA9 的温度耐受性有关。